Literature DB >> 2918060

Human corpus luteum secretion of relaxin, oxytocin, and progesterone.

F S Khan-Dawood1, L T Goldsmith, G Weiss, M Y Dawood.   

Abstract

To determine whether the human corpus luteum is a source of relaxin and oxytocin, we measured the concentrations of these peptides in plasma obtained from the ovarian veins of ovaries with and without a corpus luteum and compared these to peripheral plasma levels. Peripheral and ovarian venous blood samples were obtained from 34 nonpregnant women, 13 during the luteal phase and 21 during the follicular phase of their cycles, and from a 6-week pregnant woman. Plasma relaxin, oxytocin, and progesterone concentrations were determined by sensitive and specific RIAs. Plasma relaxin levels were not detectable (less than 0.16 microgram/L) in peripheral or ovarian venous plasma not draining a corpus luteum. The mean relaxin concentration in plasma draining an ovary with a corpus luteum was 0.41 +/- 0.09 (+/- SE) microgram/L. Oxytocin levels also were significantly higher in plasma draining an ovary with a corpus luteum (6.70 +/- 1.86 pmol/L) than in that draining the ovary with no corpus luteum (1.58 +/- 0.09 pmol/L; P less than 0.01) or in peripheral plasma (1.58 +/- 0.09 pmol/L; P less than 0.025). The mean progesterone concentration also was highest in plasma draining an ovary with a corpus luteum (210.2 +/- 50.5 nmol/L) compared with those in plasma from the contralateral ovarian vein (40.3 +/- 16.5 nmol/L P less than 0.005) and peripheral plasma (30.2 +/- 5.7 nmol/L; P less than 0.005) during the luteal phase. In a woman who was 6 weeks pregnant, plasma draining the ovary with a corpus luteum had 1.9 micrograms relaxin/L, but only 0.49 pmol/L oxytocin; the latter was similar to concentrations in noncorpus luteum-bearing ovarian venous plasma. These findings indicate that the human corpus luteum secretes relaxin, oxytocin, and progesterone. Both ovarian oxytocin and relaxin may function as paracrine or autocrine modulators of luteal function.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2918060     DOI: 10.1210/jcem-68-3-627

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  The Importance of Experimental Investigation of the Peripheral Oxytocin System.

Authors:  Stephen J Assinder
Journal:  Methods Mol Biol       Date:  2022

2.  The transcriptome-wide N6-methyladenosine (m6A) map profiling reveals the regulatory role of m6A in the yak ovary.

Authors:  Shaoke Guo; Xingdong Wang; Mengli Cao; Xiaoyun Wu; Lin Xiong; Pengjia Bao; Min Chu; Chunnian Liang; Ping Yan; Jie Pei; Xian Guo
Journal:  BMC Genomics       Date:  2022-05-11       Impact factor: 4.547

3.  Oxytocin receptors in the primate ovary: molecular identity and link to apoptosis in human granulosa cells.

Authors:  S Saller; L Kunz; G A Dissen; R Stouffer; S R Ojeda; D Berg; U Berg; A Mayerhofer
Journal:  Hum Reprod       Date:  2010-01-23       Impact factor: 6.918

4.  The pharmacokinetics of recombinant human relaxin in nonpregnant women after intravenous, intravaginal, and intracervical administration.

Authors:  S A Chen; A J Perlman; N Spanski; C M Peterson; S W Sanders; R Jaffe; M Martin; T Yalcinkaya; R C Cefalo; N C Chescheir
Journal:  Pharm Res       Date:  1993-06       Impact factor: 4.200

5.  Effect of Mode of Conception on Maternal Serum Relaxin, Creatinine, and Sodium Concentrations in an Infertile Population.

Authors:  Frauke von Versen-Höynck; Nairi K Strauch; Jing Liu; Yueh-Yun Chi; Maureen Keller-Woods; Kirk P Conrad; Valerie L Baker
Journal:  Reprod Sci       Date:  2018-06-03       Impact factor: 3.060

Review 6.  Key to Life: Physiological Role and Clinical Implications of Progesterone.

Authors:  Bernadett Nagy; Júlia Szekeres-Barthó; Gábor L Kovács; Endre Sulyok; Bálint Farkas; Ákos Várnagy; Viola Vértes; Kálmán Kovács; József Bódis
Journal:  Int J Mol Sci       Date:  2021-10-13       Impact factor: 5.923

Review 7.  Relaxin as a natural agent for vascular health.

Authors:  Daniele Bani
Journal:  Vasc Health Risk Manag       Date:  2008
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.